Latest studies
- Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaNorway - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
Endometrial CancerNorway - RecruitingNA
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
This study looks at a new way to lower ovarian cancer risk in women with certain gene changes. Instead of removing both ovaries and fallopian tubes at once, it explores removing only the fallopian tubes first, and the ovaries later, to delay menopause and its effects. We want to see if this new approach is safe and effective.
BRCA1 Gene MutationBRCA2 Gene MutationRAD51C Gene MutationRAD51D Gene MutationNorway - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerNorway - RecruitingPHASE2
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This study looks at a new medicine, Inotuzumab Ozogamicin (InO), for children aged 1 to 17 with a type of blood cancer called Acute Lymphoblastic Leukaemia (ALL) that has come back. It compares InO to a standard treatment to see which works better and is safer.
ACUTE LYMPHOBLASTIC LEUKEMIANorway - RecruitingPHASE2, PHASE3
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
This study aims to improve treatment and understanding of childhood ependymoma. It involves different treatment approaches, including chemotherapy and radiotherapy, for children and young adults up to 22 years old. The goal is to find better ways to help these patients.
Childhood EpendymomaNorway - Active not recruitingNA
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
This study aims to understand if temporarily stopping hormone therapy for early breast cancer to allow for pregnancy is safe. It will also look at fertility and emotional well-being for young women.
Early Breast CancerNorway - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
This study is looking at a new combination of two drugs, Belantamab Mafodotin and Nirogacestat, for people with multiple myeloma that has come back or not responded to previous treatments. The main goal is to find a safe dose and see how well it works.
Multiple MyelomaNorway - AuthorisedTherapeutic exploratory (Phase II)
TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis
This study looks into whether a drug called Tenofovir Alafenamide, given alongside a standard MS treatment, can help reduce nerve damage in people with multiple sclerosis by targeting the Epstein-Barr virus. It compares the drug to a dummy pill.
multiple sclerosisNorway - RecruitingPHASE2, PHASE3
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
This study is testing a new medicine, TAK-861, for people with narcolepsy type 1. It checks how safe the medicine is and if it helps reduce sleepiness and sudden muscle weakness. Participants have already taken TAK-861 in previous studies.
Narcolepsy Type 1Norway - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
RhabdomyosarcomaNorway - Active not recruitingPHASE3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
This study looks at the long-term safety of a medicine called dersimelagon (MT-7117) for people with rare skin conditions called EPP or XLP. It's for those who have already been in earlier studies for this medicine.
EPPXLPNorway - RecruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseNorway - RecruitingPHASE3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
This study looks at a medicine called IGI to see if it can help prevent infections in adults with a type of blood cancer called multiple myeloma. Participants will either get IGI for a year or only if they develop a serious infection.
Multiple MyelomaSecondary ImmunodeficiencyNorway - Active not recruitingPHASE3
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
This study is looking into a new medication called BBP-418 (also known as ribitol) for people with a muscle condition called Limb-Girdle Muscular Dystrophy type 2I (LGMD2I). It aims to see if the medication is safe and helps improve their condition.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)Norway - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Norway - RecruitingPHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is testing a new drug, linvoseltamab, for people with a type of blood cancer called multiple myeloma. It compares this new drug to standard treatments to see how safe and effective it is, for patients who cannot have a stem cell transplant.
Multiple MyelomaNorway - Active not recruitingNA
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
This study compares two ways to unblock heart arteries using stents for complex cases. It looks at whether using a special scanning tool, called OCT, during the procedure leads to better results over two years than standard methods.
Ischaemic Heart DiseaseIschemic Heart DiseaseNorway - Not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
Solid TumorsNorway - Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
This study looks at how well new migraine medicines, called CGRP drugs, work in real life. It follows people already taking these medicines for two years to see their effects and how they manage their migraine.
MigraineEpisodic MigraineChronic Migraine, HeadacheNorway - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomised, open label, multicentre study to evaluate efficacy and safety of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with peritoneal carcinomatosis from colorectal carcinoma following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
This study is testing a new treatment for bowel cancer that has spread to the tummy lining. It's for people who have already had surgery and chemotherapy. Researchers want to see if the new treatment, called Radspherin, can stop the cancer from growing back and if it's safe.
Carcinomatosis of peritoneal cavityNorway - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
This study is looking at a new combination of two drugs, belantamab mafodotin and isatuximab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to find the safest and most effective dose.
Multiple MyelomaNorway - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
High-Risk NeuroblastomaPatient With Insufficient Response ChemoimmunotherapyNorway - AuthorisedPhase I and Phase II (Integrated)- Other
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
This study is looking at a new drug, EIK1005, alone or with another approved cancer drug, Pembrolizumab. Itâs for adults with certain advanced cancers to see how safe it is and how well it works. This is an early-stage study.
Advanced Solid TumorsNorway - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
Carcinoma, Renal CellNorway - RecruitingPHASE3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
This study is for adults aged 18-75 recently diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML) or certain types of Myelodysplastic Syndrome. It tests a new drug, venetoclax, alongside standard chemotherapy, to see if this combination works better than chemotherapy alone.
Acute Myeloid LeukemiaNorway - Not yet recruitingPHASE2, PHASE3
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
This study looks at new ways to make stem cell transplants safer and more effective for children and young people with a type of blood cancer called ALL. Researchers want to reduce serious side effects and improve long-term health for these patients.
Acute Lymphoblastic Leukemia (ALL)Stem Cell TransplantGraft -Versus-host-diseaseNorway - RecruitingPHASE1, PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
This study looks at new drug combinations with isatuximab and other treatments for a type of blood cancer called multiple myeloma. It aims to find better ways to treat patients whose cancer has come back or hasn't responded to previous treatments.
Plasma Cell Myeloma RefractoryNorway - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This study looks at the long-term safety of a new medicine, itepekimab, for people with severe lung disease (COPD). It will also check if the medicine continues to help over time. Participants will have already been part of a previous study on this medicine.
Chronic Obstructive Pulmonary DiseaseNorway - RecruitingPHASE3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
This study compares a new sound wave scan (micro-ultrasound) with the current standard (MRI) for checking the prostate gland in men aged 50-70. It aims to see if the new scan is as good at finding problems, to help decide if a biopsy is needed.
Prostate Cancer ScreeningNorway - Recruiting
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
This study looks at how well a device called RefluxStop works for heartburn and acid reflux, compared to standard surgery. It checks its safety and how well it helps people with long-term acid reflux.
Gastroesophageal Reflux Disease (GERD)Norway - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
This study looks at a new medicine called empasiprubart compared to a standard treatment, IVIg, for adults with a rare muscle condition called Multifocal Motor Neuropathy (MMN). It aims to see if empasiprubart is safe and works well.
Multifocal Motor Neuropathy (MMN)MMNNorway - Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
This study looks at people who need a new heart valve after their first TAVI valve wears out. We're studying a keyhole procedure called 'Redo TAVI' (putting a new valve inside the old one), along with other treatments, to find the best ways to help patients.
Aortic Valve StenosisNorway - RecruitingPHASE2, PHASE3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
This study is looking at a new treatment called EIK1001 when given with standard treatment (Pembrolizumab) for advanced melanoma. It aims to see if this combination is safe and effective compared to Pembrolizumab alone for people whose melanoma has spread.
Advanced MelanomaNorway - Completed
Does removing both ovaries prior to menopause reduce breast cancer risk in BRCA1 and BRCA2 mutation carriers?
This study looks at existing health records to see if removing ovaries and fallopian tubes before menopause reduces breast cancer risk for women with BRCA1 or BRCA2 gene changes. It aims to understand if these operations help prevent cancer in these women.
Breast cancerNorway - Enrolling by invitationPHASE2
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
This study looks at a medicine called Infigratinib for children aged 3 to 18 with a condition called Hypochondroplasia. It's an ongoing study to understand its long-term safety and how well it helps kids who have already been part of a previous study.
HypochondroplasiaNorway - RecruitingPHASE3
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already seen benefits from the medicine in an earlier study.
Crohns DiseaseColitis, UlcerativeArthritis, PsoriaticArthritis, JuvenileNorway - Active not recruitingPHASE3
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
This study is looking at a new combination medicine, VX-121/TEZ/D-IVA, for people with cystic fibrosis. We want to understand how safe and effective it is over a longer period, especially for those who have been in previous studies with this medication.
Cystic FibrosisNorway - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
Lung Cancer, Non-squamous, Non-small CellNorway - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
Metabolic Dysfunction-Associated Steatotic Liver DiseaseNorway - Active not recruitingPHASE2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This study offers ongoing treatment for people with certain blood cancers (B-cell malignancies) who are already taking part in a different study with a drug called parsaclisib. It lets them continue their treatment if it's helping them.
B-Cell MalignanciesNorway - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
Multiple MyelomaNorway - RecruitingPHASE3
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
This study is testing a new medicine, INCA033989, against standard treatments for essential thrombocythemia (ET). It's for people with a specific gene change (CALR mutation) who have already tried other ET medicines. The aim is to see if the new medicine works better.
Essential ThrombocythemiaNorway - Active not recruitingPHASE3
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
This study looks at the long-term safety of a treatment called apraglutide for people with Short Bowel Syndrome. It's for those who were in previous studies, checking if the treatment is safe and tolerable over a longer period.
Short Bowel SyndromeNorway - RecruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
Carcinoma, Non-Small-Cell LungNorway - Active not recruitingPHASE3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.
MelanomaNorway - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerNorway - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisNorway - Active not recruitingPHASE3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous therapy. It aims to see if a new combination, IberDd, works better and is safer than a standard combination, DVd, for patients in the UK.
Multiple MyelomaNorway - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Norway